Baird analyst Colleen Kusy initiated coverage of Ocular Therapeutix with an Outperform rating and $18 price target.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on OCUL:
- AffaMed Therapeutics approved for Phase 3 trial in China for DEXTENZA
- Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
- Ocular Therapeutix sees FY23 revenue $55M-$60M, consensus $69.98M
- Ocular Therapeutix reports Q4 EPS (24c), consensus (25c)
- Ocular Therapeutix™ Provides Fourth Quarter and Year-End 2022 Results and Corporate Update